Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis

In recent years, significant changes have occurred in metastatic hormone-sensitive prostate cancer (mHSPC) management, where docetaxel and new androgen receptor pathway inhibitors (ARPI) have been shown to improve overall survival (OS) compared to androgen deprivation therapy (ADT). Recent data coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorica, Francesco, Buttigliero, Consuelo, Grigolato, Daniela, Muraro, Marco, Turco, Fabio, Munoz, Fernando, Tucci, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776703/
https://www.ncbi.nlm.nih.gov/pubmed/36547161
http://dx.doi.org/10.3390/curroncol29120747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776703/
https://www.ncbi.nlm.nih.gov/pubmed/36547161
http://dx.doi.org/10.3390/curroncol29120747

Ejemplares similares